Page 1696 - Hematology_ Basic Principles and Practice ( PDFDrive )

1512.e2 Part VIII Comprehensive Care of Patients with Hematologic Malignancies

44. Armenian SH, Sun CL, Vase T, et al: Cardiovascular risk factors in 66. Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane
hematopoietic cell transplantation survivors: role in development of as a cardioprotectant in doxorubicin-treated children with high-risk
subsequent cardiovascular disease. Blood 120(23):4505–4512, 2012. acute lymphoblastic leukaemia: long-term follow-up of a prospective,
45. Swerdlow AJ, Van Leeuwen FE: Late effects after management for randomised, multicentre trial. Lancet Oncol 11(10):950–961, 2010.
Hodgkin lymphoma. In Degos L, Linch DC, Lowenberg B, editors: 67. Lipshultz SE, Rifai N, Dalton VM, et al: The effect of dexrazoxane on
Textbook of malignant hematology, London (U.K.), 2005, Taylor & myocardial injury in doxorubicin-treated children with acute lympho-
Francis, pp 753–768. blastic leukemia. N Engl J Med 351(2):145–153, 2004.
46. Hoppe RT: Hodgkin’s disease: complications of therapy and excess 68. Asselin BL, Devidas M, Zhou T, et al: Cardioprotection and safety
mortality. Ann Oncol 8(Suppl 1):115–118, 1997. of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell
47. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic
treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol lymphoma (T-LL). J Clin Oncol 2012:9504 (abstract).
11:1208–1215, 1993. 69. Chow EJ, Asselin BL, Schwartz CL, et al: Late Mortality After Dexra-
48. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortal- zoxane Treatment: A Report From the Children’s Oncology Group.
ity from heart disease after treatment of Hodgkin’s disease. JAMA J Clin Oncol 33(24):2639–2645, 2015.
270(16):1949–1955, 1993. 70. van Dalen EC, Caron HN, Kremer LC: Prevention of anthracycline-
49. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and induced cardiotoxicity in children: the evidence. Eur J Cancer
carotid, subclavian, and coronary artery disease in survivors of hodgkin 43(7):1134–1140, 2007.
lymphoma treated with radiation therapy. JAMA 290(21):2831–2837, 71. Bryant J, Picot J, Baxter L, et al: Clinical and cost-effectiveness of
2003. cardioprotection against the toxic effects of anthracyclines given to
50. Adams MJ, Lipsitz SR, Colan SD, et al: Cardiovascular status in long- children with cancer: a systematic review. Br J Cancer 96(2):226–230,
term survivors of Hodgkin’s disease treated with chest radiotherapy. 2007.
J Clin Oncol 22(15):3139–3148, 2004. 72. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin
51. King V, Constine LS, Clark D, et al: Symptomatic coronary artery cardiotoxicity by prolonged continuous intravenous infusion. Ann
disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Intern Med 96(2):133–139, 1982.
Biol Phys 36(4):881–889, 1996. 73. Weiss AJ, Metter GE, Fletcher WS, et al: Studies on adriamycin using
52. Swerdlow AJ, Higgins CD, Smith P, et al: Myocardial infarction mortal- a weekly regimen demonstrating its clinical effectiveness and lack of
ity risk after treatment for Hodgkin disease: a collaborative British cardiac toxicity. Cancer Treat Rep 60(7):813–822, 1976.
cohort study. J Natl Cancer Inst 99(3):206–214, 2007. 74. Chlebowski RT, Paroly WS, Pugh RP, et al: Adriamycin given as a
53. Tichelli A, Bhatia S, Socie G: Cardiac and cardiovascular conse- weekly schedule without a loading course: clinically effective with
quences after haematopoietic stem cell transplantation. Br J Haematol reduced incidence of cardiotoxicity. Cancer Treat Rep 64(1):47–51,
142(1):11–26, 2008. 1980.
54. Armenian SH, Sun CL, Mills G, et al: Predictors of late cardiovascular 75. Lipshultz SE, Giantris AL, Lipsitz SR, et al: Doxorubicin admin-
complications in survivors of hematopoietic cell transplantation. Biol istration by continuous infusion is not cardioprotective: the Dana-
Blood Marrow Transplant 16(8):1138–1144, 2010. Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol
55. Greenland P, Alpert JS, Beller GA, et al: 2010 ACCF/AHA guide- 20(6):1677–1682, 2002.
line for assessment of cardiovascular risk in asymptomatic adults: a 76. Levitt GA, Dorup I, Sorensen K, et al: Does anthracycline administra-
report of the American College of Cardiology Foundation/American tion by infusion in children affect late cardiotoxicity? Br J Haematol
Heart Association Task Force on Practice Guidelines. Circulation 124(4):463–468, 2004.
122(25):e584–e636, 2010. 77. Gupta M, Steinherz PG, Cheung NK, et al: Late cardiotoxicity after
56. Baker KS, Ness KK, Steinberger J, et al: Diabetes, hypertension, and bolus versus infusion anthracycline therapy for childhood cancers. Med
cardiovascular events in survivors of hematopoietic cell transplantation: Pediatr Oncol 40(6):343–347, 2003.
a report from the bone marrow transplantation survivor study. Blood 78. Gabizon AA, Lyass O, Berry GJ, et al: Cardiac safety of pegylated
109(4):1765–1772, 2007. liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyo-
57. Lorini R, Cortona L, Scaramuzza A, et al: Hyperinsulinemia in children cardial biopsy in patients with advanced malignancies. Cancer Invest
and adolescents after bone marrow transplantation. Bone Marrow 22(5):663–669, 2004.
Transplant 15(6):873–877, 1995. 79. Marina NM, Cochrane D, Harney E, et al: Dose escalation and phar-
58. Hoffmeister PA, Storer BE, Sanders JE: Diabetes mellitus in long-term macokinetics of pegylated liposomal doxorubicin (Doxil) in children
survivors of pediatric hematopoietic cell transplantation. J Pediatr with solid tumors: a pediatric oncology group study. Clin Cancer Res
Hematol Oncol 26(2):81–90, 2004. 8(2):413–418, 2002.
59. Teinturier C, Tournade MF, Caillat-Zucman S, et al: Diabetes mellitus 80. Lowis S, Lewis I, Elsworth A, et al: A phase I study of intravenous
after abdominal radiation therapy. Lancet 346(8975):633–634, 1995. liposomal daunorubicin (DaunoXome) in paediatric patients with
60. de Vathaire F, El-Fayech C, Ben Ayed FF, et al: Radiation dose to the relapsed or resistant solid tumours. Br J Cancer 95(5):571–580, 2006.
pancreas and risk of diabetes mellitus in childhood cancer survivors: a 81. Landier W, Bhatia S, Eshelman DA, et al: Development of risk-based
retrospective cohort study. Lancet Oncol 13(10):1002–1010, 2012. guidelines for pediatric cancer survivors: the Children’s Oncology
61. Chemaitilly W, Sklar CA: Endocrine complications of hematopoietic Group Long-Term Follow-Up Guidelines from the Children’s Oncol-
stem cell transplantation. Endocrinol Metab Clin North Am 36(4):983– ogy Group Late Effects Committee and Nursing Discipline. J Clin
998, ix, 2007. Oncol 22(24):4979–4990, 2004.
62. Minotti G, Recalcati S, Menna P, et al: Doxorubicin cardiotoxicity and 82. Children’s Oncology Group: Children’s Oncology Group Long-Term
the control of iron metabolism: quinone-dependent and independent Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young
mechanisms. Methods Enzymol 378:340–361, 2004. Adult Cancers, Version 4.0. Monrovia, CA: Children’s Oncology Group,
63. Hensley ML, Hagerty KL, Kewalramani T, et al: American Society <http://www.survivorshipguidelines.org>, 2013.
of Clinical Oncology 2008 clinical practice guideline update: use 83. Majhail NS, Rizzo JD, Lee SJ, et al: Recommended screening and
of chemotherapy and radiation therapy protectants. J Clin Oncol preventive practices for long-term survivors after hematopoietic
27(1):127–145, 2009. cell transplantation. Biol Blood Marrow Transplant 18(3):348–371,
64. Kalam K, Marwick TH: Role of cardioprotective therapy for prevention 2012.
of cardiotoxicity with chemotherapy: a systematic review and meta- 84. Lund MB, Kongerud J, Nome O, et al: Lung function impairment in
analysis. Eur J Cancer 49(13):2900–2909, 2013. long-term survivors of Hodgkin’s disease. Ann Oncol 6(5):495–501,
65. van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective 1995.
interventions for cancer patients receiving anthracyclines. Cochrane 85. Hudson MM, Krasin M, Link MP, et al: Risk-adapted, combined-
Database Syst Rev (6):CD003917, 2011. modality therapy with VAMP/COP and response-based, involved-field